Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Ulipristal | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | | Ulipristal | hsa00190 | Oxidative phosphorylation | 4.36E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Ulipristal | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Ulipristal | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Ulipristal | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Ulipristal | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Ulipristal | hsa00983 | Drug metabolism - other enzymes | 3.59E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Ulipristal | hsa01230 | Biosynthesis of amino acids | 3.91E-02 | 3 | P51854, Q99707, P50213 | TKTL1, MTR, IDH3A | More | | Ulipristal | hsa03008 | Ribosome biogenesis in eukaryotes | 1.46E-02 | 4 | Q9NYH9, P78345, Q9BVP2, Q9GZY0 | UTP6, RPP38, GNL3, NXF2; NXF2B | More | | Ulipristal | hsa03013 | RNA transport | 3.27E-02 | 8 | P52298, P61326, Q9GZY0, Q14152, O75822, P78345, Q9Y6A5, Q53GS7 | NCBP2, MAGOH, NXF2; NXF2B, EIF3A, EIF3J, RPP38, TACC3, GLE1 | More | | Ulipristal | hsa03015 | mRNA surveillance pathway | 9.78E-03 | 6 | O43148, Q16537, P61326, Q9GZY0, P52298, Q53GS7 | RNMT, PPP2R5E, MAGOH, NXF2; NXF2B, NCBP2, GLE1 | More | | Ulipristal | hsa04064 | NF-kappa B signaling pathway | 4.58E-03 | 4 | Q13489, Q13546, Q9UDY8, Q9UNE0 | BIRC3, RIPK1, MALT1, EDAR | More | | Ulipristal | hsa04071 | Sphingolipid signaling pathway | 3.08E-02 | 5 | P17252, Q16537, Q9BX95, P04637, P10415 | PRKCA, PPP2R5E, SGPP1, TP53, BCL2 | More | | Ulipristal | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Ulipristal | hsa04145 | Phagosome | 3.27E-04 | 9 | P63261, Q15080, P14598, Q13509, P68371, P05164, O60603, P35443, P13765 | ACTG1, NCF4, NCF1, TUBB3, TUBB2C, MPO, TLR2, THBS4, HLA-DOB | More | | Ulipristal | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Ulipristal | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | | Ulipristal | hsa04217 | Necroptosis | 2.93E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | Ulipristal | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Ulipristal | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Ulipristal | hsa04540 | Gap junction | 3.53E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | Ulipristal | hsa04613 | Neutrophil extracellular trap formation | 2.43E-03 | 14 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P21462, P63261 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1, ACTG1 | More | | Ulipristal | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | | Ulipristal | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | Ulipristal | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Ulipristal | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Ulipristal | hsa04650 | Natural killer cell mediated cytotoxicity | 2.94E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | | Ulipristal | hsa04666 | Fc gamma R-mediated phagocytosis | 9.96E-03 | 5 | P23528, P49006, P06396, P14598, P17252 | CFL1, MARCKSL1, GSN, NCF1, PRKCA | More | | Ulipristal | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Ulipristal | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Ulipristal | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Ulipristal | hsa04972 | Pancreatic secretion | 1.99E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Ulipristal | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | | Ulipristal | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Ulipristal | hsa05132 | Salmonella infection | 1.43E-03 | 11 | Q9UJU2, P63261, Q13546, Q13489, P10415, O60603, Q9BQS8, Q13561, O60282, Q13509, P68371 | LEF1, ACTG1, RIPK1, BIRC3, BCL2, TLR2, FYCO1, DCTN2, KIF5C, TUBB3, TUBB2C | More | | Ulipristal | hsa05140 | Leishmaniasis | 7.29E-04 | 7 | P14598, P13765, O60603, P25963, P29350, P49006, Q15080 | NCF1, HLA-DOB, TLR2, NFKBIA, PTPN6, MARCKSL1, NCF4 | More | | Ulipristal | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Ulipristal | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | | Ulipristal | hsa05202 | Transcriptional misregulation in cancer | 6.80E-03 | 12 | Q12778, Q15532, P41732, P14780, P14923, Q13489, O15550, P04637, P05164, P08246, Q9C0K0, P24522 | FOXO1, SS18, TSPAN7, MMP9, JUP, BIRC3, UTX, TP53, MPO, ELA2, BCL11B, GADD45A | More | | Ulipristal | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Ulipristal | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Ulipristal | hsa05205 | Proteoglycans in cancer | 2.66E-02 | 8 | Q14643, P63261, P04637, P14780, P17252, O60603, Q13635, P08962 | ITPR1, ACTG1, TP53, MMP9, PRKCA, TLR2, PTCH1, CD63 | More | | Ulipristal | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Ulipristal | hsa05216 | Thyroid cancer | 3.59E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Ulipristal | hsa05217 | Basal cell carcinoma | 1.46E-02 | 4 | Q13635, Q9UJU2, P04637, P24522 | PTCH1, LEF1, TP53, GADD45A | More | | Ulipristal | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Ulipristal | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Ulipristal | hsa05323 | Rheumatoid arthritis | 3.53E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Ulipristal | hsa05418 | Fluid shear stress and atherosclerosis | 4.26E-02 | 6 | P14598, P14780, P63261, P04637, P10415, Q92974 | NCF1, MMP9, ACTG1, TP53, BCL2, ARHGEF2 | More | | |